Gilead Sciences, Inc.

GILD
Passed

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Country
US
Market Cap
$101.26B
Last Fiscal Year
2023
Final Shariah Status
Passed
Compliance Analysis Overview

Shariah Compliance Benchmarks:

  • Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
  • Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
Business Compliance
0.00% passed
5% Threshold
0.0%
Liabilities Compliance
24.68% passed
33% Threshold
24.7%
Final Shariah Status
Passed

This stock meets all Shariah compliance criteria according to AAOIFI standards.

Stock Information
Name Gilead Sciences, Inc.
Ticker GILD
Main Business delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas.
Type Common Stock
Industry Drug Manufacturers—General
Country US
Market Cap $101.26 B

Shariah Analysis Breakdown

Business compliance Breakdown
Revenue Segment Value ($M) Non-Compliant ($M) Reason
Product sales $26,982.0 $0.0 -
Royalty, contract and other revenues $299.0 $0.0 -
Total $27,281.0 $0.0 0.00% (passed)
Liabilities Compliance Breakdown
Liability Item Value ($M) % of Market Cap
current debt and capital lease obligation $1,800,000,000.0 1.78%
long term debt and capital lease obligation $23,190,000,000.0 22.90%
Total Interest-Bearing Debt $24,990,000,000.0 24.68%
Market Capitalization $101,262,500,000.0 100.00%
Compliance Status Threshold: 33% passed